Arctic Bioscience — Investor Presentation 2026

May 8, 2026

Arctic Bioscience presents HeROPA data at EADV in Athens

Arctic Bioscience presents HeROPA data at EADV in Athens

Arctic Bioscience is presenting key results from the HeROPA study at the

European Academy of Dermatology and Venereology (EADV) Symposium in Athens,

Greece, 7-9th May 2026. The data shows statistically significant difference in

key psoriasis endpoints compared to placebo in patients with lower baseline

systemic immune-inflammatory index (SII), while no such difference was observed

in patients with higher baseline SII.

The poster "Beyond skin deep: Baseline systemic immune-inflammatory index as

predictor of treatment response of HRO350 in mild-to-moderate psoriasis. Results

from the HeROPA study", shows that patients with SII at or below the median had

greater response to HRO350 compared to placebo across several endpoints in the

per-protocol population. In contrast, patients with SII above median showed no

benefit from HRO350 compared to placebo and this group showed tendencies for

higher placebo rates.

Differences in response rates between the low and high SII groups exceeded 25

percentage points for several skin symptom endpoints and were statistically

significant.

The safety data derived from this study, which included over 500 patients, shows

a favorable safety and tolerability profile for HRO350.

Coordinating investigator for the HeROPA trial, Professor Ingeborg Bachmann from

Haukeland University Hospital, is first author of the poster.

"It is very positive that we are presenting results from the HeROPA study at

such a prestigious scientific event. As a Norwegian biotech company, it is a

major milestone to conduct and complete a phase 2b clinical trial of this size.

This publication, and other future publications from the study, will support the

ongoing partnering dialogues for future development of HRO350", says CEO

Christer Valderhaug.

"It is a milestone and an honor to present data from the HeROPA study at the

EADV Symposium. We have used SII as a biomarker to look at how high inflammatory

load the patients had, and this has helped us understand the data from the

study. Inflammation is a key driver for psoriasis, and these data show that the

patients with a less severe inflammation in the blood respond best to HRO350,

which supports the positioning of HRO350 in mild-to-moderate psoriasis. I am

very grateful to the patients who participated, and it is my hope that the

results can contribute to treatment advances for patients with mild-to-moderate

psoriasis, who have so few treatment options today" says medical director

Runhild Gammelsæter, who attends the EADV in Athens.

Reference:

Bachmann I, Ringheim-Bakka T, Meland N, Smerud K, Kirby B,

Gammelsaeter R. "Beyond skin deep: Baseline systemic immune-inflammatory index

as predictor of treatment response of HRO350 in mild-to-moderate psoriasis.

Results from the HeROPA study". Poster ID P1125, Abstract ID-727, EADV

Symposium, Athens, Greece, May 7-9th, 2026.

The poster will also be made available on the IR tab on the company's webpage.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.